MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
TSX:MDP - Toronto Stock Exchange - CA58410Q2036 - Common Stock - Currency: CAD
MDP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 33 industry peers in the Pharmaceuticals industry. While MDP has a great profitability rating, there are some minor concerns on its financial health. MDP has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year MDP was profitable.
In the past year MDP had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MDP reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: MDP reported negative operating cash flow in multiple years.
1.2 Ratios
MDP has a better Return On Assets (1.31%) than 81.82% of its industry peers.
MDP has a better Return On Equity (4.31%) than 81.82% of its industry peers.
The Return On Invested Capital of MDP (11.52%) is better than 93.94% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MDP is in line with the industry average of 8.20%.
The 3 year average ROIC (9.89%) for MDP is below the current ROIC(11.52%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.31% | ||
| ROE | 4.31% | ||
| ROIC | 11.52% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 2.07%, MDP is in the better half of the industry, outperforming 78.79% of the companies in the same industry.
The Operating Margin of MDP (11.00%) is better than 84.85% of its industry peers.
MDP has a better Gross Margin (52.23%) than 81.82% of its industry peers.
MDP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11% | ||
| PM (TTM) | 2.07% | ||
| GM | 52.23% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDP is creating some value.
The number of shares outstanding for MDP has been increased compared to 1 year ago.
The number of shares outstanding for MDP has been increased compared to 5 years ago.
The debt/assets ratio for MDP has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.57, we must say that MDP is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.57, MDP is in the better half of the industry, outperforming 69.70% of the companies in the same industry.
MDP has a debt to FCF ratio of 1.74. This is a very positive value and a sign of high solvency as it would only need 1.74 years to pay back of all of its debts.
The Debt to FCF ratio of MDP (1.74) is better than 93.94% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that MDP is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, MDP belongs to the top of the industry, outperforming 84.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.74 | ||
| Altman-Z | 0.57 |
ROIC/WACC1.19
WACC9.71%
2.3 Liquidity
A Current Ratio of 0.83 indicates that MDP may have some problems paying its short term obligations.
The Current ratio of MDP (0.83) is worse than 84.85% of its industry peers.
MDP has a Quick Ratio of 0.83. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MDP has a Quick ratio of 0.47. This is in the lower half of the industry: MDP underperforms 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.47 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 900.00% over the past year.
The Revenue has decreased by -4.18% in the past year.
Measured over the past years, MDP shows a small growth in Revenue. The Revenue has been growing by 7.82% on average per year.
EPS 1Y (TTM)900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)-4.18%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-4.65%
3.2 Future
MDP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.29% yearly.
The Revenue is expected to grow by 10.09% on average over the next years. This is quite good.
EPS Next Y-221.2%
EPS Next 2Y116.13%
EPS Next 3Y102.56%
EPS Next 5Y53.29%
Revenue Next Year-6.57%
Revenue Next 2Y5.72%
Revenue Next 3Y9.64%
Revenue Next 5Y10.09%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 25.82 indicates a quite expensive valuation of MDP.
MDP's Price/Earnings ratio is rather cheap when compared to the industry. MDP is cheaper than 84.85% of the companies in the same industry.
When comparing the Price/Earnings ratio of MDP to the average of the S&P500 Index (28.04), we can say MDP is valued inline with the index average.
MDP is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.82 | ||
| Fwd PE | N/A |
4.2 Price Multiples
MDP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDP is cheaper than 93.94% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MDP is valued cheaply inside the industry as 96.97% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.16 | ||
| EV/EBITDA | 4.14 |
4.3 Compensation for Growth
The decent profitability rating of MDP may justify a higher PE ratio.
A more expensive valuation may be justified as MDP's earnings are expected to grow with 102.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y116.13%
EPS Next 3Y102.56%
5. Dividend
5.1 Amount
No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MDP (7/25/2025, 7:00:00 PM)
2.84
+0.06 (+2.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners2.98%
Inst Owner ChangeN/A
Ins Owners7.25%
Ins Owner ChangeN/A
Market Cap91.62M
Analysts80
Price Target6.59 (132.04%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)64.09%
Min EPS beat(2)58.46%
Max EPS beat(2)69.73%
EPS beat(4)3
Avg EPS beat(4)31.55%
Min EPS beat(4)-100%
Max EPS beat(4)98.02%
EPS beat(8)5
Avg EPS beat(8)29.87%
EPS beat(12)8
Avg EPS beat(12)78.18%
EPS beat(16)9
Avg EPS beat(16)-34.63%
Revenue beat(2)1
Avg Revenue beat(2)3.19%
Min Revenue beat(2)-0.44%
Max Revenue beat(2)6.82%
Revenue beat(4)2
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-0.44%
Max Revenue beat(4)6.82%
Revenue beat(8)3
Avg Revenue beat(8)-1.09%
Revenue beat(12)6
Avg Revenue beat(12)0.63%
Revenue beat(16)8
Avg Revenue beat(16)0.96%
PT rev (1m)5.6%
PT rev (3m)5.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)5.28%
Revenue NQ rev (3m)5.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.82 | ||
| Fwd PE | N/A | ||
| P/S | 0.62 | ||
| P/FCF | 3.16 | ||
| P/OCF | 2.8 | ||
| P/B | 1.29 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.14 |
EPS(TTM)0.11
EY3.87%
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)0.9
FCFY31.67%
OCF(TTM)1.01
OCFY35.72%
SpS4.57
BVpS2.2
TBVpS-1.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.31% | ||
| ROE | 4.31% | ||
| ROCE | 16% | ||
| ROIC | 11.52% | ||
| ROICexc | 16.98% | ||
| ROICexgc | N/A | ||
| OM | 11% | ||
| PM (TTM) | 2.07% | ||
| GM | 52.23% | ||
| FCFM | 19.67% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.74 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 37.98% | ||
| Cap/Sales | 2.52% | ||
| Interest Coverage | 2.79 | ||
| Cash Conversion | 125.84% | ||
| Profit Quality | 948.29% | ||
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.47 | ||
| Altman-Z | 0.57 |
F-Score5
WACC9.71%
ROIC/WACC1.19
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y-221.2%
EPS Next 2Y116.13%
EPS Next 3Y102.56%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-4.18%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-4.65%
Revenue Next Year-6.57%
Revenue Next 2Y5.72%
Revenue Next 3Y9.64%
Revenue Next 5Y10.09%
EBIT growth 1Y-6.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.11%
EBIT Next 3Y62.77%
EBIT Next 5Y51.43%
FCF growth 1Y15.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.43%
OCF growth 3YN/A
OCF growth 5YN/A